A phase 1/2 study combining ipilimumab with abiraterone acetate plus prednisone in chemotherapy- and immunotherapy-naive patients with progressive metastatic castration resistant prostate cancer
Latest Information Update: 11 Oct 2024
At a glance
- Drugs Ipilimumab (Primary) ; Abiraterone acetate; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 08 Oct 2024 Planned End Date changed from 1 Sep 2024 to 1 Sep 2025.
- 08 Oct 2024 Planned primary completion date changed from 1 Sep 2024 to 1 Sep 2025.
- 11 Sep 2023 Planned End Date changed from 1 Sep 2023 to 1 Sep 2024.